Preprint · OA
via OpenAlex
Translational development of mesenchymal stem cell therapy for cardiovascular diseases.
Europe PMC (PubMed Central) · 2009 · ▲ 25 citations
Abstract
Currently, a growing number of small clinical trials are testing the impact of cell-based therapies for heart disease.1 In order to guide future approaches, it is important in the context of these trials to consider issues pertaining to mechanism of action.2 To date, the bone marrow3 has been the most widely studied source of cell-based therapy for heart disease, and this has been followed by skeletal myoblasts.4 With regard to the bone marrow, both whole mononuclear bone marrow and cultured bone-marrow–derived mesenchymal stem cells (MSCs) have entered clinical trials. There have been attempts to study the impact of cell-based therapy for patients who have had an acute myocardial infarction or who have ischemic heart failure, and in the latter case both ventricular remodeling and hibernating myocardium have been targeted.
At present, the University of Miami has 2 trials in active enrollment and a 3rd in the planning stage. The goal of the current trials is to test the hypothesis that injected MSCs can produce reverse remodeling in the chronically infarcted heart by reducing the scar burden and improving cardiac structure and function. In parallel studies performed in pigs, we have tested the fate of injected cells and have documented engraftment, the formation of new myocytes (unpublished observations), and vessel growth.5 Thus, our program currently targets the treatment of chronic ischemic cardiomyopathy. This disorder, in comparison with acute myocardial infarction, requires special consideration of the delivery method, and we have chosen to focus on direct delivery in the operating room or via a percutaneous injection system.
The development of cell-based therapy is still at a stage in which the primary goal is to establish safety, which is to say that most studies are at Phase I. Nevertheless, sophisticated imaging methods, such as cardiac magnetic resonance imaging (MRI), provide the opportunity to obtain surrogate efficacy markers as a secondary endpoint.
Preclinical Studies. In order to convincingly establish safety and efficacy, we developed a relevant preclinical model for ischemic cardiomyopathy in adult mini-pigs. The results of these studies were instrumental in providing the Food and Drug Administration with preclinical safety information as part of an IND application, and were also useful in performing studies regarding the mechanism of action of the cell therapy.
A porcine model was chosen due to the anatomic similarity between the porcine and human hearts, particularly with regard to coronary anatomy. A significant problem with pigs is the steep growth rate of immature animals, rendering them too large to fit in an MRI magnet, which is the primary imaging device used in these studies. In addition, the rapid rate of growth could confound interpretation of cardiac anatomy. To solve this problem, we created a model of ischemic cardiomyopathy in adult Gottingen mini-pigs.6 The animals are studied at approximately 18 months of age. At this point, they weigh 35 to 40 kilograms, and for the next 6 months they will gain only another 5 kilograms. Reproducible transmural infarctions, affecting 20% to 25% of the left ventricle, can be created in the animals by occluding for 2.5 hours the left-anterior descending coronary artery with an angioplasty balloon. The scars, generally localized on the anteroseptal wall, were allowed to heal for 3 months. During the subsequent 3-month interim, autologous mesenchymal stem cells were amplified from a bone-marrow aspirate and then surgically delivered in the operating room under direct visualization via injections administered throughout the scar and its border zone. The scar was the direct target of the therapy, the goal being to replace it with functional tissue.
In regard to the safety evaluation, animals were monitored for arrhythmias, laboratory blood tests were performed serially after injection, and whole-body autopsies were performed 3 months after the injections. Overall, the approach was very safe: no adverse events, anticipated or unanticipated, occurred. Of note, the whole-body autopsies found no ectopic tissue in the heart or elsewhere.
These preclinical studies demonstrated the very substantial repair potential of the therapy.7 We used cardiac MRI to monitor the animals over the course of the studies, and—by administering cells at doses comparable to those used in current trials (20 million and 200 million cells per heart)—we reduced infarct size by approximately 25% and increased ejection fraction significantly, in comparison with pre-injection values. These effects were not present in the control group.
Clinical Trials for Ischemic Cardiomyopathy. With these data in hand, we received approval from the Food and Drug Administration for the PROMETHEUS study (Prospective Randomized assessment Of MEsenchymal stem cell THErapy in patients Undergoing Surgery). The study, funded through the National Heart, Lung, and Blood Institute's Specialized Center for Cell Therapeutics (SCCT), enrolls patients who require coronary artery bypass surgery and who have ejection fractions between 0.20 and 0.50 due to a previous myocardial infarction that caused segmental left ventricular akinesis or dyskinesis. The patient can enter the study if he or she meets enrollment criteria and consents to participate, and if the patient's surgeons and independent clinicians deem it safe to wait 4 to 5 weeks between bone-marrow harvest and treatment. The 4 to 5 weeks are necessary in order to amplify the autologous mesenchymal stem cells with which patients are treated at the time of surgery. The study groups are placebo, low-dose (20-million), and high-dose (200-million) MSC groups. The study has a rigorous design: double-blind, randomized, and placebo-controlled. All patients undergo bone-marrow aspiration and cardiac injection. An independent Data Safety and Monitoring Board monitors the study, under the auspices of the National Institut
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Hare, J.M. (2009). Translational development of mesenchymal stem cell therapy for cardiovascular diseases. <em>Europe PMC (PubMed Central)</em>. https://openalex.org/W194983857
Vancouver
Hare JM. Translational development of mesenchymal stem cell therapy for cardiovascular diseases. Europe PMC (PubMed Central). 2009.
BibTeX
@unpublished{joshua2009Transl,
title = {Translational development of mesenchymal stem cell therapy for cardiovascular diseases.},
author = {Joshua M. Hare},
journal = {Europe PMC (PubMed Central)},
year = {2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
European Heart Journal 2009
Open access · OA
Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy
Rejuvenation Research 2010
Citation only
The Effect of Age on the Efficacy of Human Mesenchymal Stem Cell Transplantation after a Myocardial Infarction
PubMed 2009
Preprint · OA
Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy.
Circulation Research 2011
Open access · OA
Mesenchymal Stem Cells
Expert Opinion on Biological Therapy 2023
Preprint · OA
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells
Journal of the American Geriatrics Society 2020
Open access · OA